Stephen Migueles

Title: The Innovative Contributions of Stephen Migueles

Introduction

Stephen Migueles is a notable inventor based in Washington, DC, who has made significant strides in the field of immunology. His work primarily focuses on developing engineered T cell receptors that target human immunodeficiency virus (HIV). With a patent to his name, Migueles has contributed to advancing our understanding of immune responses against HIV-infected cells.

Latest Patents

Stephen Migueles holds a patent for "Human immunodeficiency virus-specific T cell receptors." This patent describes engineered TCR molecules that are specific to retroviral peptide/HLA complexes. These molecules guide direct killing and enable robust immune responses against HIV-infected cells. The TCR fusion polypeptide comprises a TCR variable alpha (Vα) domain, a TCR variable beta domain (Vβ), and a TCR constant region domain (C), specifically designed to target HIV peptides.

Career Highlights

Throughout his career, Migueles has worked with prominent organizations, including Altor Bioscience Corporation and the United States Department of Health and Human Services. His contributions have been pivotal in the ongoing fight against HIV, showcasing his dedication to improving public health through innovative research.

Collaborations

Stephen Migueles has collaborated with esteemed colleagues such as Peter Rhode and Mark Connors. These partnerships have further enhanced his research efforts and have contributed to the development of effective therapeutic strategies against HIV.

Conclusion

In summary, Stephen Migueles is a distinguished inventor whose work in engineered T cell receptors has the potential to transform HIV treatment. His innovative approach and collaborations highlight the importance of research in combating viral infections.